{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T11:13:07Z","timestamp":1767093187265},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.canlet.2010.03.018","type":"journal-article","created":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T08:51:25Z","timestamp":1272012685000},"page":"74-87","source":"Crossref","is-referenced-by-count":7,"title":["Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells"],"prefix":"10.1016","volume":"296","author":[{"given":"Jie","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Hudder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Zukowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond F.","family":"Novak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2010.03.018_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2010.03.018_bib2","first-page":"614","article-title":"Therapeutic options in the management of metastatic breast cancer","volume":"22","author":"Higgins","year":"2008","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.canlet.2010.03.018_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3816\/CBC.2008.n.025","article-title":"Metastatic breast cancer: the treatment challenge","volume":"8","author":"Jones","year":"2008","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.canlet.2010.03.018_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1006461422273","article-title":"Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells","volume":"65","author":"Santner","year":"2001","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2010.03.018_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1023\/A:1026562720218","article-title":"Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunochemical markers","volume":"64","author":"Strickland","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2010.03.018_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1006461422273","article-title":"Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells","volume":"65","author":"Steven","year":"2001","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2010.03.018_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1023\/A:1009577811584","article-title":"Xenograft models of premalignant breast disease","volume":"5","author":"Miller","year":"2000","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/j.canlet.2010.03.018_bib8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1517\/13543784.14.3.313","article-title":"Inhibitors of the mammalian target of rapamycin","volume":"14","author":"Dancey","year":"2005","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.canlet.2010.03.018_bib9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3816\/CBC.2003.n.018","article-title":"Mammalian target of rapamycin: a new molecular target for breast cancer","volume":"4","author":"Mita","year":"2003","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.canlet.2010.03.018_bib10","doi-asserted-by":"crossref","first-page":"R1097","DOI":"10.1186\/bcr1344","article-title":"Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts","volume":"7","author":"Kasukabe","year":"2005","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2010.03.018_bib11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/erc.0.0080249","article-title":"mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer","volume":"8","author":"Yu","year":"2001","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2010.03.018_bib12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/1078-0432.CCR-03-0043","article-title":"Determinants of rapamycin sensitivity in breast cancer cells","volume":"10","author":"Noh","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2010.03.018_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1356-9597.2004.00727.x","article-title":"Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function","volume":"9","author":"Oshiro","year":"2004","journal-title":"Genes Cells"},{"key":"10.1016\/j.canlet.2010.03.018_bib14","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1158\/1535-7163.MCT-05-0400","article-title":"Targeting the Akt\/mammalian target of rapamycin pathway for radiosensitization of breast cancer","volume":"5","author":"Albert","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2010.03.018_bib15","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2010.03.018_bib16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cell.2004.12.040","article-title":"The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation","volume":"120","author":"Beuvink","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2010.03.018_bib17","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1535-7163.MCT-05-0005","article-title":"Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo","volume":"4","author":"Luo","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2010.03.018_bib18","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1038\/sj.onc.1210343","article-title":"Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition","volume":"26","author":"Han","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2010.03.018_bib19","first-page":"6075","article-title":"Isolation and characterization of a spontaneously immortalized human breast epithelial cell line MCF-10","volume":"50","author":"Soule","year":"1990","journal-title":"Cancer Res."},{"issue":"Pt 2","key":"10.1016\/j.canlet.2010.03.018_bib20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1242\/jcs.99.2.453","article-title":"Morphological expression of cell transformation induced by c-Ha-ras oncogene in human breast epithelial cells","volume":"99","author":"Russo","year":"1991","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2010.03.018_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mc.2940040106","article-title":"Transformation of human breast epithelial cells by c-Ha-ras oncogene","volume":"4","author":"Basolo","year":"1991","journal-title":"Mol. Carcinogen."},{"key":"10.1016\/j.canlet.2010.03.018_bib22","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1002\/ijc.24278","article-title":"Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions biomarkers of progression","volume":"124","author":"Kim","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2010.03.018_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1677\/erc.1.01172","article-title":"p53 and breast cancer an update","volume":"13","author":"Lacroix","year":"2006","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2010.03.018_bib24","first-page":"202","article-title":"Advances in the management of localized breast cancer: an overview","volume":"102","author":"Chagpar","year":"2004","journal-title":"J. Kentucky Med. Assoc."},{"key":"10.1016\/j.canlet.2010.03.018_bib25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ctrv.2008.01.007","article-title":"Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer","volume":"34","author":"Coley","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.canlet.2010.03.018_bib26","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/1078-0432.CCR-04-0112","article-title":"Activation of the Akt\/mammalian target of rapamycin\/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers","volume":"10","author":"Zhou","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2010.03.018_bib27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nature08221","article-title":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","volume":"460","author":"Harrison","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2010.03.018_bib28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1126\/science.1177221","article-title":"Ribosomal protein S6 kinase 1 signaling regulates mammalian life span","volume":"326","author":"Selman","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.canlet.2010.03.018_bib29","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1158\/1535-7163.MCT-06-0646","article-title":"Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors","volume":"6","author":"Kurmasheva","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2010.03.018_bib30","first-page":"205","article-title":"Targeting PI3K-AKT pathway for cancer therapy","volume":"7","author":"Lu","year":"2003","journal-title":"Rev. Clin. Exp. Hematol."},{"key":"10.1016\/j.canlet.2010.03.018_bib31","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/sj.bjc.6602162","article-title":"Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer","volume":"91","author":"Chan","year":"2004","journal-title":"Brit. J. Cancer."},{"key":"10.1016\/j.canlet.2010.03.018_bib32","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1158\/1078-0432.CCR-04-0361","article-title":"Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells","volume":"10","author":"Mondesire","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2010.03.018_bib33","doi-asserted-by":"crossref","first-page":"8184","DOI":"10.1128\/MCB.22.23.8184-8198.2002","article-title":"Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells","volume":"22","author":"Law","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2010.03.018_bib34","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.transproceed.2008.10.009","article-title":"mTOR-what does it do?","volume":"40","author":"Hall","year":"2008","journal-title":"Transplant Process."},{"key":"10.1016\/j.canlet.2010.03.018_bib35","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-08-0668","article-title":"Increased Akt S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K\/mTOR inhibition","volume":"8","author":"Breuleux","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2010.03.018_bib36","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1158\/0008-5472.CAN-08-3014","article-title":"TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-ser2481 is a marker for intact mTOR signaling complex 2","volume":"69","author":"Copp","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.03.018_bib37","article-title":"Targeted Therapy: Comprehensive Review","author":"Costa","year":"2009","journal-title":"Am. J. Hospice Palliat. Care."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383510001795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383510001795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T16:55:32Z","timestamp":1635267332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383510001795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0304383510001795"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2010.03.018","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}